Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Bighin

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Tumori|May 7, 2002
Herceptin in elderly patientsClaudia Bighin, Ilaria Stevani, Marco Venturini
JMIR Research Protocols|April 29, 2025
Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping ReviewLinda Battistuzzi, Irene Giannubilo, Claudia Bighin
Future Oncology (London, England)|July 11, 2013
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patientsClaudia Bighin, Paolo Pronzato, Lucia Del Mastro
The Oncologist|March 16, 2026
Prognostic disclosure in metastatic breast cancer: a scoping reviewLinda Battistuzzi, Irene Giannubilo, Eva Blondeaux, et al.
Frontiers in Medicine|May 16, 2022
EU-Funded Telemedicine Projects - Assessment of, and Lessons Learned From, in the Light of the SARS-CoV-2 PandemicLaura Paleari, Virginia Malini, Gabriella Paoli, et al.
Leukemia Research|April 7, 2012
Stevens-Johnson syndrome after treatment with bendamustineMatteo Lambertini, Lucia Del Mastro, Giovanni Gardin, et al.
Expert Review of Anticancer Therapy|October 18, 2012
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patientsLucia Del Mastro, Matteo Lambertini, Claudia Bighin, et al.
The Oncologist|December 15, 2010
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitorsClaudia Bighin, Gianluigi Lunardi, Lucia Del Mastro, et al.
International Journal of Cancer|February 18, 2010
Use in current clinical practice of 70-gene signature in early breast cancerClaudia Bighin, Lucia Del Mastro, Giuseppe Canavese, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2015
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trialMatteo Lambertini, Paolo Bruzzi, Francesca Poggio, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Tumori|May 7, 2002
Herceptin in elderly patientsClaudia Bighin, Ilaria Stevani, Marco Venturini
JMIR Research Protocols|April 29, 2025
Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping ReviewLinda Battistuzzi, Irene Giannubilo, Claudia Bighin
Future Oncology (London, England)|July 11, 2013
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patientsClaudia Bighin, Paolo Pronzato, Lucia Del Mastro
The Oncologist|March 16, 2026
Prognostic disclosure in metastatic breast cancer: a scoping reviewLinda Battistuzzi, Irene Giannubilo, Eva Blondeaux, et al.
Frontiers in Medicine|May 16, 2022
EU-Funded Telemedicine Projects - Assessment of, and Lessons Learned From, in the Light of the SARS-CoV-2 PandemicLaura Paleari, Virginia Malini, Gabriella Paoli, et al.
Leukemia Research|April 7, 2012
Stevens-Johnson syndrome after treatment with bendamustineMatteo Lambertini, Lucia Del Mastro, Giovanni Gardin, et al.
Expert Review of Anticancer Therapy|October 18, 2012
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patientsLucia Del Mastro, Matteo Lambertini, Claudia Bighin, et al.
The Oncologist|December 15, 2010
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitorsClaudia Bighin, Gianluigi Lunardi, Lucia Del Mastro, et al.
International Journal of Cancer|February 18, 2010
Use in current clinical practice of 70-gene signature in early breast cancerClaudia Bighin, Lucia Del Mastro, Giuseppe Canavese, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2015
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trialMatteo Lambertini, Paolo Bruzzi, Francesca Poggio, et al.
Pageof 6